Journal of global antimicrobial resistance · 2026
Comparative colistin sulfate vs. polymyxin B in patients with carbapenem-resistant organism bloodstream infections.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Yingxia, Huang Tianmin, Zhu Donglan, Luo Yilin, Feng Huansheng, Wei Meiquan, Qin Luyao, Niu Lulu, Wu Yun, Luo Jun, Liu Taotao
Аннотация
OBJECTIVES: To compare the efficacy and safety of colistin sulfate (CS) vs. polymyxin B (PMB) sulfate in treating patients with carbapenem-resistant organism bloodstream infections (CRO-BSI).
METHODS: We conducted a retrospective cohort study of adult patients with CRO-BSI (January 2022-June 2025) treated with intravenous CS or PMB. The primary outcome was 28-d all-cause mortality. Secondary outcomes were clinical treatment response, microbiological clearance and acute kidney injury (AKI). We used 1:1 propensity-score matching to balance baseline covariates and performed multivariate Cox regression to adjust for potential confounders.
RESULTS: After matching (60 patients per group), 28-d mortality was similar between CS and PMB (33% vs. 30%; P = 0.70). Clinical effectiveness (35% vs. 28%) and microbiological clearance (68% vs. 62%) did not differ significantly (all P > 0.4). In contrast, AKI was less frequent with CS (13% vs. 28%; P = 0.043). Multivariate Cox analysis confirmed no significant mortality difference (adjusted HR for CS vs. PMB, 0.68; 95% CI 0.33-1.40; P = 0.293).
CONCLUSIONS: CS and PMB were equally effective in treating patients with CRO-BSI, but the CS group experienced a lower rate of AKI.
METHODS: We conducted a retrospective cohort study of adult patients with CRO-BSI (January 2022-June 2025) treated with intravenous CS or PMB. The primary outcome was 28-d all-cause mortality. Secondary outcomes were clinical treatment response, microbiological clearance and acute kidney injury (AKI). We used 1:1 propensity-score matching to balance baseline covariates and performed multivariate Cox regression to adjust for potential confounders.
RESULTS: After matching (60 patients per group), 28-d mortality was similar between CS and PMB (33% vs. 30%; P = 0.70). Clinical effectiveness (35% vs. 28%) and microbiological clearance (68% vs. 62%) did not differ significantly (all P > 0.4). In contrast, AKI was less frequent with CS (13% vs. 28%; P = 0.043). Multivariate Cox analysis confirmed no significant mortality difference (adjusted HR for CS vs. PMB, 0.68; 95% CI 0.33-1.40; P = 0.293).
CONCLUSIONS: CS and PMB were equally effective in treating patients with CRO-BSI, but the CS group experienced a lower rate of AKI.